Fatigue in immune-mediated neuropathies

Neuromuscular Disorders

Volumn 22, Issue SUPPL. 3, 2012, Pages

  Merkies, Ingemar S J ^a,b   Faber, Catharina G ^b  

^a Infection and Immunology   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CIDP; Fatigue; GBS; Immune mediated neuropathies; MGUSP; MMN

Indexed keywords

ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FATIGUE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE MEDIATED NEUROPATHY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; NEUROPATHY; PATHOGENESIS; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADICULOPATHY;

CHRONIC DISEASE; DEMYELINATING DISEASES; GUILLAIN-BARRE SYNDROME; HUMANS; MUSCLE FATIGUE; POLYRADICULONEUROPATHY; QUALITY OF LIFE;

EID: 84870050389     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.10.014     Document Type: Article

References (45)

1. Van den Bergh P.Y., Hadden R.D., Bouche P., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010, 17:356-363.
2. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J Peripher Nerv Syst 2010;15:1-9.
3. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010;15:295-301.
4. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010;15:185-95.
5. Merkies I.S., Schmitz P.I., van der Meche F.G., Samijn J.P., van Doorn P.A. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002, 59:84-91.
6. Merkies I.S., Hughes R.A., Donofrio P., et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010, 15:208-215.
7. Bernsen R.A., Jacobs H.M., de Jager A.E., van der Meche F.G. Residual health status after Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1997, 62:637-640.
8. Merkies I.S., Schmitz P.I., van der Meche F.G., Samijn J.P., van Doorn P.A. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003, 74:99-104.
9. Merkies I.S., Schmitz P.I., Samijn J.P., van der Meche F.G., van Doorn P.A. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Neurology 1999, 53:1648-1654.
10. Wessely S., Powell R. Fatigue syndromes: a comparison of chronic " postviral" fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry 1989, 52:940-948.
11. Gregory R.J. Understanding and coping with neurological impairment. Rehabil Nurs 1995, 20:74-78.
12. Khan F., Pallant J.F., Ng L., Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol 2010, 257:2024-2031.
13. Garssen M.P., Bussmann J.B., Schmitz P.I., et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 2004, 63:2393-2395.
14. Erdmann P.G., Lindeman E., Cats E.A., van den Berg L.H. Functioning of patients with multifocal motor neuropathy. J Peripher Nerv Syst 2010, 15:113-119.
15. Kyriakides T., Papacostas S., Papanicolaou E., Bagdades E., Papathanasiou E.S. Sleep hypoventilation syndrome and respiratory failure due to multifocal motor neuropathy with conduction block. Muscle Nerve 2011, 43:610-614.
16. Chaudhuri A., Behan P.O. Fatigue in neurological disorders. Lancet 2004, 363:978-988.
17. de Vries J.M., Hagemans M.L., Bussmann J.B., van der Ploeg A.T., van Doorn P.A. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol Life Sci 2010, 67:701-713.
18. Schillings M.L., Kalkman J.S., Janssen H.M., van Engelen B.G., Bleijenberg G., Zwarts M.J. Experienced and physiological fatigue in neuromuscular disorders. Clin Neurophysiol 2007, 118:292-300.
19. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121-1123.
20. Drory V.E., Bronipolsky T., Bluvshtein V., Catz A., Korczyn A.D. Occurrence of fatigue over 20 years after recovery from Guillain-Barre syndrome. J Neurol Sci 2012, 316:72-75.
21. Forsberg A., Press R., Holmqvist L.W. Residual disability 10 years after falling ill in Guillain-Barre syndrome: a prospective follow-up study. J Neurol Sci 2012, 317:74-79.
22. Davidson I., Wilson C., Walton T., Brissenden S., Campbell M., McGowan L. What constitutes a 'good' recovery outcome in post-acute Guillain-Barre syndrome? Results of a nationwide survey of post-acute GBS sufferers in the United Kingdom. Eur J Neurol 2010, 17:677-683.
23. Bissay V., Flamez A., Schmedding E., Ebinger G. Fatigue as the presenting symptom of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008, 38:1653-1657.
24. Boukhris S., Magy L., Gallouedec G., et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. J Peripher Nerv Syst 2005, 10:329-337.
25. Bussmann J.B., Garssen M.P., van Doorn P.A., Stam H.J. Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Rehabil Med 2007, 39:121-125.
26. Garssen M.P., Van Koningsveld R., Van Doorn P.A. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. J Neurol 2006, 253:1143-1146.
27. Rekand T., Gramstad A., Vedeler C.A. Fatigue, pain and muscle weakness are frequent after Guillain-Barre syndrome and poliomyelitis. J Neurol 2009, 256:349-354.
28. Westblad M.E., Forsberg A., Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil 2009, 31:720-725.
29. Cats E.A., van der Pol W.L., Piepers S., et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010, 75:818-825.
30. Dittner A.J., Wessely S.C., Brown R.G. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res 2004, 56:157-170.
31. DeVellis R.F. Classical test theory. Med Care 2006, 44:S50-S59.
32. Stucki G., Daltroy L., Katz J.N., Johannesson M., Liang M.H. Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 1996, 49:711-717.
33. Svensson E. Guidelines to statistical evaluation of data from rating scales and questionnaires. J Rehabil Med 2001, 33:47-48.
34. Rasch G. Probabilistic models for some intelligence and attainment tests 1960, University of Chicago Press, Chicago.
35. Tennant A., Conaghan P.G. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?. Arthritis Rheum 2007, 57:1358-1362.
36. van Nes S.I., Vanhoutte E.K., Faber C.G., Garssen M., van Doorn P.A., Merkies I.S. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst 2009, 14:268-278.
37. Garssen M.P., van Doorn P.A., Visser G.H. Nerve conduction studies in relation to residual fatigue in Guillain-Barre syndrome. J Neurol 2006, 253:851-856.
38. Ware J.E., Kosinski M., Gandek B. SF-36® health survey. Manual and interpretation guide 2000, Lincoln, RI, QualityMetric Incorporated.
39. Garssen M.P., Schmitz P.I., Merkies I.S., Jacobs B.C., van der Meche F.G., van Doorn P.A. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry 2006, 77:61-65.
40. Krupp L.B., Coyle P.K., Doscher C., et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961.
41. Rat A.C., Pouchot J., Fautrel B., Boumier P., Goupille P., Guillemin F. Factors associated with fatigue in early arthritis: results from the ESPOIR cohort. Arthritis Care Res (Hoboken) 2012, 64(7):1061-1069.
42. Cleanthous S., Tyagi M., Isenberg D.A., Newman S.P. What do we know about self-reported fatigue in systemic lupus erythematosus?. Lupus 2012, 21:465-476.
43. Bager P., Befrits R., Wikman O., et al. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment Pharmacol Ther 2012, 35:133-141.
44. Smets E.M., Garssen B., Schuster-Uitterhoeve A.L., de Haes J.C. Fatigue in cancer patients. Br J Cancer 1993, 68:220-224.
45. Naess H., Lunde L., Brogger J., Waje-Andreassen U. Fatigue among stroke patients on long-term follow-up. The Bergen stroke study. J Neurol Sci 2012, 312:138-141.